Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Human Colorectal Cancer Stage-dependent Global DNA Hypomethylation of Cancer-associated Fibroblasts

EDUARD LING, AMIT RINGEL, INA SIGAL-BATIKOFF, NAIM ABU-FREHA, HANANYA VAKNINE, WLEDY FRIAH, AVRAHAM RESHEF, ILIA PINSK, ALEXANDER FICH and SERGIO LAMPRECHT
Anticancer Research September 2016, 36 (9) 4503-4507;
EDUARD LING
1Pediatrics Department B, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel
2Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AMIT RINGEL
2Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
3Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer Sheva, Israel
4Institute of Gastroenterology and Hepatology, Soroka University Medical Center, Beer Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
INA SIGAL-BATIKOFF
2Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
3Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer Sheva, Israel
4Institute of Gastroenterology and Hepatology, Soroka University Medical Center, Beer Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAIM ABU-FREHA
2Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
4Institute of Gastroenterology and Hepatology, Soroka University Medical Center, Beer Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANANYA VAKNINE
5Institute of Pathology, Wolfson Medical Center, Holon, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WLEDY FRIAH
2Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
4Institute of Gastroenterology and Hepatology, Soroka University Medical Center, Beer Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AVRAHAM RESHEF
2Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
6Surgery Department B, Soroka University Medical Center, Beer Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ILIA PINSK
2Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
7Unit of Colorectal Surgery, Soroka University Medical Center, Beer Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEXANDER FICH
2Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
4Institute of Gastroenterology and Hepatology, Soroka University Medical Center, Beer Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SERGIO LAMPRECHT
2Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
3Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer Sheva, Israel
4Institute of Gastroenterology and Hepatology, Soroka University Medical Center, Beer Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sergiol{at}bgu.ac.il
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Cancer-associated fibroblasts (CAFs) play an important role in tumor development and progression. The prevailing consensus favors the view that a specific epigenetic signature underpins the stable CAF phenotype. The aim of the present study was to assess global DNA methylation in CAFs during the adenoma–carcinoma sequence in non-familial sporadic human colorectal cancer (CRC). Patients and Methods: Immunohistochemical staining of nuclear 5-methylcytosine (5’-meCyt) was performed in matched samples of colonic tumor tissue and normal colonic mucosa excised from six patients with adenomas and four with adenocarcinomas. The staining intensity was expressed semi-quantitatively as the immunohistochemical staining score (ISS). Results: ISS values of human colonic CAFs and adenomatous samples were 14.00±2.2 and 14.08±1.8, respectively, showing no statistically significant difference. In contrast, a marked trend was found towards global DNA hypomethylation in CAFs from adenocarcinomatous specimens compared to matched normal mucosa: ISS: 9.25±2.44 (range=6-11) vs. 16.17±0.75, respectively, p<0.03. Conclusion: Final stages of cancer development in CRC are associated with global DNA hypomethylation in stromal CAFs.

  • Methylation
  • fibroblasts
  • colorectal cancer

Traditionally, studies of neoplastic growth have focused on molecular events in tumor cells, whereas the stromal fibroblasts surrounding the tumor mass were considered mere bystanders and, consequently, their role in cancer development and progression have remained largely neglected. Accruing information is now available showing that these mesenchymal cells are conscripted and educated by the adjacent cancer cells and as cancer-associated fibroblasts (CAFs) they participate in a malevolent alliance with their rogue neighbors, promoting their unrelenting growth and invasive program (1-4). Of note, however, evidence [reviewed in (5)] shows that this is not invariably the case: stromal components may act to impede early-stage tumorigenesis. In this scenario, the desmoplastic response represents an initial host defense designed to restrain the growth of the incipient tumor. A characteristic hallmark of CAFs is that they can be propagated in vitro and in vivo for extended periods of time without loss of their cancer-promoting phenotype (6, 7). Much evidence favors the prevailing opinion that this phenotypic stability is due to cancer-imposed epigenetic changes rather than to clonal somatic mutations (8-12) [reviewed in (3, 4, 13-14)].

Epigenetics refers to somatically inheritable changes in gene expression that do not require changes in DNA nucleotide sequence. A salient example of epigenetics is the control of gene activity by DNA methylation, i.e. the addition of a methyl group to the 5’ carbon of the pyrimidine cytosine within a DNA CpG dinucleotide sequence, an enzymatic reaction catalyzed by DNA methyltransferases (DNMTs) (Figure 1). Methylation extends through the promoter and start site of a gene and typically prohibits the critical interaction of transcription factors with DNA-response elements. Thereby, DNA site-specific hypermethylation is associated with heterochromatin and gene silencing. Conversely, DNA hypomethylation results in transcriptionally active euchromatin leading to brisk gene expression (15).

Global DNA hypomethylation has been described in CAFs derived from a large number of solid tumors including human gastric carcinomas (10, 11). An early work reported global DNA hypomethylation in the stromal proteoglycan versican gene in human colonic carcinoma cells (16), an interesting observation since full-length human recombinant versican expression in cultured murine fibroblasts was shown to induce a myofibroblast-like phenotype (17), a well-recognized hallmark of CAFs.

The aim of the present study was to assess global DNA methylation in CAFs at the various stages of the human non-familial sporadic CRC adenoma–adenocarcinoma sequence using a validated immunohistochemical assay that reports the staining intensity of 5’-methyl cytosine (5’-meCyt) in the cell nucleus.

Materials and Methods

Patients. Colonic tissues were obtained from biopsies taken from eight patients at various stages of the CRC adenoma–carcinoma sequence who underwent colonoscopy at the Institute of Gastroenterology and Hepatology, Soroka University Medical Center, Beer Sheba, Israel. This group consisted of two patients with adenocarcinomas and six with adenomas. Specimens of colonic adenocarcinomas were also obtained from two patients who underwent surgery at the Surgery Division, Soroka University Medical Center, Beer Sheba, Israel, and, collectively, the colonic adenocarcinoma group consisted of four patients, The adenoma group consisted of three patients with tubular adenomas (benign polyps) and three with tubulovillous adenomas (prone to malignancy) diagnosed by a senior pathologist.

Biopsy specimens of intact colonic mucosa were obtained from macroscopically normal colonic mucosa located at least 5 cm from the tumor margin. All tissue specimens were fixed in formalin and embedded in paraffin, and 4 μm tissue sections were used for further studies. All patients signed an informed consent form. The study was approved by the Ethics Committee of Soroka University Medical Center in compliance with the ethical standards of the Helsinki Declaration: Clinical numbers: 0140-12-SOR, 033-14-SOR.

Immunohistochemistry. Figure 1 shows the epigenetic reaction leading to methylation of the DNA nucleotide cytosine. All chemicals of highest purity grade available were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA) unless stated otherwise. Nuclear 5’-meCyt was detected using a mouse monoclonal antibody (162 33 D3; Calbiochem, Merck Millipore, Darmstadt, Germany) raised against 5-meCyt conjugated to ovoalbumin, tested previously in human gastric CAFs (10) and in a human colonic myofibroblast cell line (Ling E, unpublished observation). The protocol was as described by Jiang et al. (10) with minor modifications. Briefly, tissue sections were deparaffinized in xylene and rehydrated in graded alcohol series. Antigen retrieval was performed in boiling 100 mM citrate buffer (pH 6.0) for 20 min with subsequent cooling at room temperature for an additional 20 min. Following wash in phosphate-buffered saline (PBS), the tissue sections were exposed to 3.5 N HCl for 15 min at room temperature to induce DNA denaturation. Following washing in PBS and 20-min incubation with 0.3% H2O2 in absolute methanol for quenching endogenous peroxidase activity, and an additional wash in PBS, tissue sections were incubated with 1.5% horse serum for 60 min at room temperature and then with anti-5’meCyt at 1:500 dilution in 1% albumin solution in PBS for 24 hours at 4°C. Antibody detection was performed using Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) with diaminobenzidine substrate according to the manufacturer's instructions. Slides were counterstained with hematoxylin, dehydrated and mounted. The majority of slides contained both pathological and normal tissue sections, when such slides were not available, both control and pathological tissue sections were treated identically.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Methylation of DNA cytosine catalyzed by DNA methyltransferase (DNMT). A methyl group (-CH3) is enzymatically transferred from S-adenosylmethionine (SAM) to the 5’ carbon of the pyrimidine cytosine (in red) within a DNA CpG dinucleotide sequence. The monoclonal antibody used in this study specifically recognizes the methylated cytosine.

Pathological evaluation. The intensity of nuclear staining of fibroblasts adjacent to adenomas or carcinomas was compared to that of resident fibroblasts in the lamina propria of normal colonic mucosa. Additionally, the intensity of staining of fibroblasts was compared to staining of normal and malignant epithelial cells and of lymphocytes found in the stromal tissue. These types of cells (epithelial cells and accompanying lymphocytes) were chosen to serve as internal control for two reasons: firstly, the nuclear staining of these cells for 5’-meCyt is well documented (18) and, secondly, the variability of staining of epithelial cells and lymphocytes was low. Nuclear staining intensity was scored as low (score 1), moderate (score 2) and intense (score 3), respectively. The high intensity score of 3 was defined as the staining intensity of cells in the adjacent epithelial cells and of lymphocytes. Cell scoring for nuclear 5’-meCyt staining was performed by a senior pathologist using a double-headed light microscope. The scoring system was based on global assessment of staining in all fibroblast nuclei in the entire high-power field compared with that in epithelial cells in the same field. The intensity of staining was evaluated in six randomized high-power fields of 2 mm2 per slide and scoring was expressed as the average density per 1 mm2 field.

Statistical analysis. Wilcoxon signed-rank test was used to evaluate the association between dependent variables. Each slide was assigned a final score which was based on the sum of individual intensity scores of each power field. Four groups were defined for statistical purposes: adenomatous specimens versus normal tissue specimens, and adenocarcinomatous samples versus normal tissue samples. The nuclear staining intensity scores of tumor surgical specimens were pooled with those of biopsy specimens. The statistical analysis was performed using IBM SPSS software (SPSS 19.0 for Windows; SPSS Inc, Chicago, IL, USA); a value of p<0.05 was considered statistically significant.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Immunostaining for nuclear 5’-methyl cytosine (5’-meCyt) of normal human stromal colonic fibroblasts (A) and cancer-associated fibroblasts (CAFs) (B). A: The intensity of 5’-meCyt staining in normal stromal fibroblasts (black arrows) is markedly higher than that expressed in CAFs (B), and comparable to that of normal colonic epithelial cells (red dashed arrows). B: The intensity of 5’-meCyt staining in CAFs (black arrows), markedly lower compared to normal stromal fibroblasts (A) and to adjacent adenocarcinomatous epithelial cells (red dashed arrows), indicates global DNA hypomethylation. Representative slides (original magnification ×400) are shown.

Results

Global DNA methylation in stromal fibroblasts of colonic tubular and tubulovillous adenomas. Tissue specimens of six patients with colonic adenomas were examined. In all samples, the nuclei of epithelial cells (normal, adenomatous and carcinomatous), stromal fibroblasts and lymphocytes within the lamina propria stained positively for 5-meCyt (data not shown). The mean nuclear intensity score of 5’-meC staining of fibroblasts in normal colonic mucosa was 14.08±1.83 (range=12-16), whereas the respective value for CAFs in the stroma of colonic adenomas was found to be 14.00±2.2 (range=11-17): This difference was not statistically significant.

Global DNA hypomethylation in stromal fibroblasts of colonic adenocarcinomas. Colonic mucosa specimen of four patients with colonic adenocarcinomas were examined. In all samples, nuclei of epithelial cells, stromal fibroblasts and intraepithelial lymphocytes stained positively for 5’-meC; however, a markedly reduced nuclear staining intensity of stromal CAF adenocarcinoma was consistently found compared to their counterparts in normal mucosa. The score of nuclear staining intensity revealed a significant (p<0.03) loss of nuclear staining of colonic adenocarcinoma CAFs compared to stromal fibroblasts surrounding the normal colonic mucosa (Figure 2): The nuclear staining intensity score in CAFs was 9.25±2.44 (range=6-13) vs. 16.17±0.75 (range=15-17) in normal stromal fibroblasts.

No difference in staining intensity of epithelial cells and intraepithelial lymphocytes between normal tissue and adenocarcinoma tissue was found (Figure 2).

Discussion

Our results indicate that, similarly to other gastrointestinal regions (10), significant changes in the epigenetic signature are a hallmark of colonic CAFs in human CRC. Notably, global DNA hypomethylation, assessed by immunostaining of nuclear 5’-meCyt, was fully established in stromal colonic CAFs at the adenocarcinoma CRC stage. Interestingly, no difference in nuclear 5’meCyt intensity staining was noted between colonic benign polyps or polyps prone to malignancy and normal stromal fibroblasts.

In a series of preliminary experiments (19) designed to provide direct evidence that cancer cells instruct colonic fibroblasts to acquire a CAF-like phenotype, we previously assessed global DNA methylation in a human normal colonic myofibroblast line (CCD-18Co) co-cultered in a Transwell system with HT-29 cells, a human colonic adenocarcinoma cell line. Global DNA methylation was quantified by a microplate-based assay. The exposure of colonic fibroblasts to cancer cells resulted in a marked time-dependent loss of DNA methylation. These findings, albeit preliminary, indicate that sustained paracrine cross-talk of CCD-18Co cells with cancer cells changes the epigenetics of colonic fibroblasts.

Our findings concord with those reported by Mrazek et al. (20). These investigators used genomic-wide gene-microarray expression and Illumina-based methylation analysis to study cultured colonic CAFs collected from stroma surrounding colonic adenocarcinomas. Their results indicated differential expression of genes and DNA methylation of promoter regions specific to CAFs. As noted in other solid tumor types (11), global DNA hypomethylation was associated with focal DNA hypermethylation.

What are the putative molecular mechanisms underpinning changes in the epigenetic landscape of colonic CAFs in terms of global DNA methylation? Neoplastic cells induce a chronic inflammatory response that builds up an inflammatory pro-tumorigenic microenvironment (TME) (21, 22). In addition, CAFs maintain the inflammatory TME by expressing a pro-inflammatory gene signature and by acting as brisk recruiters of pro-inflammatory cells. Therefore, in a vicious self-sustaining train of events, both tumor cells and CAFs contribute to the TME inflammasome (23-25).

A vast body of evidence is available showing that pro-inflammatory cytokines are able to exert their action on key components of the epigenetic machinery (12, 26, 27). Among them, transforming growth factor-β (TGFβ) plays a determinant role and findings indicate that a frequent site of TGFβ intervention is the regulation of DNMTs involved in DNA methylation [Figure 1 (28), reviewed in (29). Interestingly, Hawinkels and co-workers presented evidence that levels of active TGFβ1 are increased in human colonic tissue at the adenocarcinoma stage (30), to wit, at the CRC stage in which frank changes in CAF epigenetic landscape were observed in this study. Of note, a high level of TGFβ in CRC tumors correlates with disease relapse (31).

As discussed previously, DNA hypomethylation is associated with proficient chromatin and brisk activity of transcription factors. We surmise that among the newly-expressed genes are well-recognized markers of the CAF trait such as cyclooxygenase (COX2), a potential oncogenic enzyme, and fibroblastic-activation protein (FAP), an enzyme involved in the remodeling of the extracellular matrix (4, 24). Concordant with this view, FAP was shown to be expressed in CAFs surrounding colorectal carcinomas (32), and high FAP expression in CRC was shown to be associated with poor patient prognosis (33).

Epigenetic changes, unlike genetic ones, are potentially reversible and can be interfered with by drugs (14). Our observation that colonic CAFs express frank changes in their epigenetic signature predominantly at the adenocarcinoma stage of CRC may indicate a critical timing when administration of drugs able to reverse epigenetic changes in CRC could be beneficial.

A limitation of the present study is that only global DNA methylation in CRC CAFs was examined, and a deliberate characterization of the DNA methylome must include the assessment of gene promoter site-specific methylation signature. Moreover, our approach precludes any information on possible phenotypic and functional heterogeneity of colonic stromal CAFs (34). An attractive line of research, poorly explored to date, should also address specific histone post-translational modifications in stromal fibroblasts. We surmise that in addition to changes in the DNA methylome, histone changes greatly contribute to the stable CAF phenotype and, thereby, they sustain the role of CAFs in promoting the opportunistic growth agenda of cancer cells.

Footnotes

  • Conflicts of Interests

    None.

  • Received June 21, 2016.
  • Revision received August 11, 2016.
  • Accepted August 17, 2016.
  • Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Kalluri R,
    2. Zeisberg M
    : Fibroblasts in cancer. Nat Rev Cancer 6: 392-401, 2006.
    OpenUrlCrossRefPubMed
    1. Orimo A,
    2. Weinberg R
    : Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 5: 1597-1601, 2006.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Madar S,
    2. Goldstein I,
    3. Rotter V
    : Cancer-associated fibroblasts - more than meets the eye. Trends Mol Med 19: 447-453, 2013.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Polanska U,
    2. Orimo A
    : Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 228: 1651-1657, 2013.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Delinasios JG,
    2. Angeli F,
    3. Koumakis G,
    4. Kumar S,
    5. Kang WH,
    6. Sica G,
    7. Iacopino F,
    8. Lama G,
    9. Lamprecht S,
    10. Sigal-Batikoff I,
    11. Tsangaris GT,
    12. Farfarelos CD,
    13. Farfarelos MC,
    14. Vairaktaris E,
    15. Vassiliou S,
    16. Delinasios GJ
    : Proliferating fibroblasts and HeLa cells co-cultured in vitro reciprocally influence growth patterns, protein expression, chromatin features and cell survival. Anticancer Res 35: 1881-1916, 2015.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Orimo A,
    2. Gupta PB,
    3. Sgroi DC,
    4. Arenzana-Seisdedos F,
    5. Delaunay T,
    6. Naeem R,
    7. Carey VJ,
    8. Richardson AL,
    9. Weinberg RA
    : Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348, 2005.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Olumi AF,
    2. Grossfeld GD,
    3. Hayward SW,
    4. Carroll PR,
    5. Tlsty TD,
    6. Cunha GR
    : Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59: 5002-5011, 1999.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Fiegl H,
    2. Millinger S,
    3. Goebel G,
    4. Müller-Holzner E,
    5. Marth C,
    6. Laird PW,
    7. Widschwendter M
    : Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 66: 29-33, 2006.
    OpenUrlAbstract/FREE Full Text
    1. Hu M,
    2. Yao J,
    3. Cai L,
    4. Bachman KE,
    5. van den Brûle F,
    6. Velculescu V,
    7. Polyak K
    : Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genetics 37: 899-905, 2005.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Jiang L,
    2. Gonda TA,
    3. Gamble MV,
    4. Salas M,
    5. Seshan V,
    6. Tu S,
    7. Twaddell WS,
    8. Hegyi P,
    9. Lazar G,
    10. Steele I,
    11. Varro A,
    12. Wang TC,
    13. Tycko B
    : Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res 68: 9900-9908, 2008.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Vizoso M,
    2. Puig M,
    3. Carmona FJ,
    4. Maqueda M,
    5. Velásquez A,
    6. Gómez A,
    7. Labernadie A,
    8. Lugo R,
    9. Gabasa M,
    10. Rigat-Brugarolas LG,
    11. Trepat X,
    12. Ramírez J,
    13. Moran S,
    14. Vidal E,
    15. Reguart N,
    16. Perera A,
    17. Esteller ML,
    18. Alcaraz J
    : Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts. Carcinogenesis 36: 1453-1463, 2015.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Albrengues J,
    2. Bertero T,
    3. Grasset E,
    4. Bonan S,
    5. Maiel M,
    6. Bourget I1,
    7. Philippe C,
    8. Herraiz Serrano C,
    9. Benamar S,
    10. Croce O,
    11. Sanz-Moreno V,
    12. Meneguzzi G,
    13. Feral CC,
    14. Cristofari G,
    15. Gaggioli C
    : Epigeneitic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nature Comm 6: 10204, 2015.
    OpenUrl
  11. ↵
    1. Rudnick S,
    2. Kuperwasser C
    : Stromal biomarkers in breast cancer development and progression. Clin Exp Metastasis 29: 663-72, 2012.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Gonda T,
    2. Varro A,
    3. Wang T,
    4. Tycko B
    : Molecular biology of cancer associated fibroblasts: Can these cells be targeted in anticancer therapy? Semin Cell Dev Biol 21: 2-10, 2010.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Kouzarides T
    : Chromatin modifications and their function. Cell 128: 693-705, 2007.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Adany R,
    2. Iozzo R
    : Altered methylation of versican proteoglycan gene in human colon carcinoma. Biochem Biophys Res Comm 171: 1402-1413, 1990.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Carthy JM,
    2. Meredith AJ,
    3. Boroomand S,
    4. Abraham T,
    5. Luo Z,
    6. Knight D,
    7. McManus BM
    : Versican V1 overexpression induces a myofibroblast-like phenotype in cultured fibroblasts. PLoS One 10: e0133056, 2015.
    OpenUrlPubMed
  16. ↵
    1. Hinoi T,
    2. Akyol A,
    3. Theisen BK,
    4. Ferguson DO,
    5. Greenson JK,
    6. Williams BO,
    7. Cho KR,
    8. Fearon ER
    : Mouse model of colonic adenoma–carcinoma progression based on somatic Apc inactivation. Cancer Res 67: 9721-9730, 2007.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Lamprecht S,
    2. Deliniasos J,
    3. Fich A,
    4. Abu-Freha N
    : Do cancer cells impose epigenetic changes on normal fibroblasts? A colon-oriented preliminary inquiry. Anticancer Res 34: 6020-6021, 2014.
    OpenUrl
  18. ↵
    1. Mrazek AA,
    2. Carmical JR,
    3. Wood TG,
    4. Hellmich MR,
    5. Eltorky M,
    6. Bohanon FJ,
    7. Chao C
    : Colorectal cancer-associated fibroblasts are genotypically distinct. Curr Cancer Ther Rev 10: 97-218, 2014.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Rokavec M,
    2. Öner M,
    3. Hermeking H
    : lnflammation-induced epigenetic switches in cancer. Cell Mol Life Sci 73: 23-39, 2016.
    OpenUrlPubMed
  20. ↵
    1. Abu-Remaileh M,
    2. Bender S,
    3. Raddatz G,
    4. Ansari I,
    5. Cohen D,
    6. Gutekunst J,
    7. Musch T,
    8. Linhart H,
    9. Breiling A,
    10. Pikarsky E,
    11. Bergman Y,
    12. Lyko F
    : Chronic inflammation induces a novel epigenetic program that is conserved in intestinal adenomas and in colorectal cancer. Cancer Res 75: 2120-2130, 2015.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Erez N,
    2. Glanz S,
    3. Raz Y, C,
    4. Avivi C,
    5. Barshack I
    : Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem Biophys Res Commun 437: 397-402, 2013.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Erez N,
    2. Truitt M,
    3. Olson P,
    4. Arron S,
    5. Hanahan D
    : Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17: 135-147, 2010.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Servais C,
    2. Erez N
    : From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J Pathol 229: 198-207, 2013.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Landskron G,
    2. de la Fuente M,
    3. Thuwajit P,
    4. Thuwajit C,
    5. Hermoso MA
    : Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014: 149185, 2014.
    OpenUrlPubMed
  25. ↵
    1. Hodge DR,
    2. Peng B,
    3. Cherry JC,
    4. Hurt EM,
    5. Fox SD,
    6. Kelley JA,
    7. Munroe DJ,
    8. Farrar WL
    : Interleukin 6 supports the maintenance of p53 tumor-suppressor gene promoter methylation. Cancer Res 65: 4673-4682, 2005.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Pan X,
    2. Chen Z,
    3. Huang R,
    4. Yao Y,
    5. Ma G
    : Transforming growth factor β 1 induces the expression of collagen type I by DNA methylation in cardiac fibroblasts. Plos One 8: e60335, 2013.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Pickup M,
    2. Novitskiy S,
    3. Moses H
    : The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 13: 788-799, 2013.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Hawinkels LJ,
    2. Verspaget HW,
    3. van der Reijden JJ,
    4. van der Zon JM,
    5. Verheijen JH,
    6. Hommes DW,
    7. Lamers CB,
    8. Sier CF
    : Active TGF-beta1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence. Cancer Sci 100: 663-670, 2009.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Calon A,
    2. Lonardo E,
    3. Berenguer-Llergo A,
    4. Espinet E,
    5. Hernando-Momblona X,
    6. Iglesias M,
    7. Sevillano M,
    8. Palomo-Ponce S,
    9. Tauriello DVF,
    10. Byrom D,
    11. Cortina C,
    12. Morral C,
    13. Barceló C,
    14. Tosi S,
    15. Riera A,
    16. Attolini CS-O,
    17. Rossell D,
    18. Sancho E,
    19. Batlle E
    : Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 47: 320-329, 2015.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Koczorowska MM,
    2. Tholen S,
    3. Bucher F,
    4. Lutz L,
    5. Kizhakkedathu JN,
    6. De Wever O,
    7. Wellner UF,
    8. Biniossek ML,
    9. Stahl A,
    10. Lassmann S,
    11. Schilling O
    : Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Mol Oncol 10: 40-58, 2016.
    OpenUrlPubMed
  31. ↵
    1. Wikberg M,
    2. Edin S,
    3. Lundberg I,
    4. van Guelpen B
    : High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol 34: 1013-1020, 2013.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Ohlund D,
    2. Elyada E,
    3. Tuveson D
    . Fibroblast heterogeneity in the cancer wound: J Exp Med 211: 1503-1523, 2014.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 36, Issue 9
September 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Human Colorectal Cancer Stage-dependent Global DNA Hypomethylation of Cancer-associated Fibroblasts
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Human Colorectal Cancer Stage-dependent Global DNA Hypomethylation of Cancer-associated Fibroblasts
EDUARD LING, AMIT RINGEL, INA SIGAL-BATIKOFF, NAIM ABU-FREHA, HANANYA VAKNINE, WLEDY FRIAH, AVRAHAM RESHEF, ILIA PINSK, ALEXANDER FICH, SERGIO LAMPRECHT
Anticancer Research Sep 2016, 36 (9) 4503-4507;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Human Colorectal Cancer Stage-dependent Global DNA Hypomethylation of Cancer-associated Fibroblasts
EDUARD LING, AMIT RINGEL, INA SIGAL-BATIKOFF, NAIM ABU-FREHA, HANANYA VAKNINE, WLEDY FRIAH, AVRAHAM RESHEF, ILIA PINSK, ALEXANDER FICH, SERGIO LAMPRECHT
Anticancer Research Sep 2016, 36 (9) 4503-4507;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Vitamin D and Myofibroblasts in Fibrosis and Cancer: At Cross-purposes with TGF-{beta}/SMAD Signaling
  • Google Scholar

More in this TOC Section

  • POM121 Drives Gastric Cancer Progression via the mTOR/p70S6K Signaling Axis
  • Glutamine Dependence Is Not a Cancer-specific Vulnerability in Contrast to Methionine Dependence
  • mTOR Modulation Affects Galectin-1 Expression in KMT2A-rearranged Acute Lymphoblastic Leukemia Cells
Show more Experimental Studies

Keywords

  • methylation
  • fibroblasts
  • Colorectal cancer
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire